

**EDUCATIONAL COURSE:  
Preclinical and early-phase clinical pharmacology**

**6<sup>th</sup> February 2019**



**40<sup>th</sup> EORTC-PAMM Winter Meeting**

**7<sup>th</sup> – 9<sup>th</sup> February 2019**

**Palazzo della Gran Guardia,  
piazza Bra, Verona – Italy**

**PROGRAMME**

**PAMM Board**

Eric Raymond, France, Chair

Annette Larsen, France

Elisa Giovannetti, The Netherlands

Godefridus J. Peters, The Netherlands

**Scientific Committee**

Andrea Bonetti, Italy

Brian Leyland-Jones, USA

Etienne Chateleut, France

Paola Perego, Italy

Joseph Ciccolini, France

Godefridus J. Peters, The Netherlands

Elisa Giovannetti, The Netherlands

Roger M. Phillips, UK

Monika Hegi, Switzerland

Eric Raymond, France

Georg Hempel, Germany

Christian Rolfo, Belgium

Markus Joerger, Switzerland

Andrzej Skladanowski, Poland

Annette Larsen, France

Andrew D. Westwell, UK

Roberto Leone, Italy

Nadia Zaffaroni, Italy

## Local Organizing Committee

Andrea Bonetti

Department of Oncology  
Mater Salutis Hospital Legnago  
Verona, Italy

Roberto Leone

Department of Diagnostic and Public  
Health, Section of Pharmacology,  
University of Verona, Italy

## Sponsorship and Cooperation

REGIONE DEL VENETO



UNIVERSITÀ  
di **VERONA**



AZIENDA OSPEDALIERA  
UNIVERSITARIA INTEGRATA  
VERONA



ORDINE DEI MEDICI  
CHIRURGHI ED  
ODONTOIATRI DELLA  
PROVINCIA DI VERONA



Rete Oncologica Veneta  
Ricerca, innovazione, assistenza



**CIPOMO**

Collegio Italiano dei Primari Oncologi  
Medici Ospedalieri



**GOIRC**

GRUPPO ONCOLOGICO ITALIANO  
DI RICERCA CLINICA

In cooperation with

ESO Recommended Event



# WEDNESDAY 6<sup>TH</sup> FEBRUARY

## EDUCATIONAL COURSE: PRECLINICAL AND EARLY-PHASE CLINICAL PHARMACOLOGY

- Chairs: Paola Perego, Italy and Godefridus J. Peters, The Netherlands
- 9.00-9.25 **How to perform pharmacological studies in vitro**  
Paola Perego, Molecular Pharmacology Unit, Istituto Nazionale dei Tumori Milano, Italy
- 9.25-9.50 **To combine or not to combine: drug interactions and tools for their analysis**  
Godefridus J. Peters, Laboratory Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
- 9.50-10.15 **Realistic preclinical approaches: hypoxia and 3D models**  
Roger Phillips, School of Applied Sciences, University of Huddersfield, UK
- 10.15-10.30 *Continuous Coffee Break*
- 10.30-10.55 **How to navigate among the OMICS data and their correlation with pharmacological data**  
Giovanni Ciriello, Dept. Computational Biology, University of Lausanne, Switzerland
- 10.55-11.20 **Drug development, after the NCI-compounds initiative**  
Hans Hendriks, Hendriks Pharmaceutical Consulting, Purmerend, The Netherlands
- 11.20-11.45 **Neighborhood matters: new tools and practical approaches for co-culturing cancer cells**  
Elisa Giovannetti, Amsterdam University Medical Center, VU University, The Netherlands
- 11.45-12.45 **Practical session on data analysis and technical aspects**
- 12.45-13.45 *Free Time for Lunch*
- 13.45-14.45 **Practical session on OMICS data**
- 14.45-15.00 **Introduction to pharmacometrics**  
Georg Hempel, Institut für Pharmazeutische und Medizinische Chemie, - Klinische Pharmazie, Westfälische Wilhelms-Universität Münster, Germany
- 15.00-15.25 **Pharmacometrics with immunotherapy**  
Joseph Ciccolini, Pharmacokinetics Laboratory, Centre de Recherche en Cancérologie de Marseille, Aix-Marseille Université, France
- 15.25-15.50 **PK, PD, first dose and schedule selection in phase I**  
Eric Raymond, Oncologie Médicale, Centre Hospitalier Paris Saint-Joseph, France
- 15.50-16.05 **Final discussion with Q&A**

19.00 **EORTC-PAMM WINTER MEETING, WELCOME COCKTAIL**

# THURSDAY 7<sup>TH</sup> FEBRUARY

## SESSION I: THE MODERN LANDSCAPE AND NEW AVENUES IN THE TREATMENT OF MALIGNANCIES

Chairs: Erik Raymond, France and Nadia Zaffaroni, Italy

- 8.30-9.00 **Inhibitors of deubiquitinases: from preclinical to clinical studies**  
Stig Linder, Karolinska Institute, Linköping University, Sweden
- 9.00-9.30 **Host-microbe co-metabolism and cancer drug efficacy**  
Filipe Cabreiro, Birkbeck University of London, United Kingdom
- 9.30-10.00 **The role of the microbiome in immunotherapy**  
Lisa Derosa, Institut Gustave Roussy, France
- 10.00-10.30 **Metabolic hallmarks of tumor and immune cells in the tumor microenvironment.**  
Marina Kreutz, University of Regensburg, Germany
- 10.30-11.00 *Coffee break, poster viewing*
- 11.00-11.30 **Next generation histopathological diagnosis: from omics to clinical applications**  
Aldo Scarpa, University of Verona, Italy
- 11.30-12.00 **Does the dose of monoclonal antibody make matter?**  
Etienne Chatelut, University of Toulouse, France
- 12.00-12.30 **Is pharmacometrics the missing link of immunotherapy?**  
Joseph Ciccolini, University of Marseille, France
- 12.30-13.00 **The immune suppressive myeloid environment in cancers**  
Vincenzo Bronte, University of Verona, Italy
- 13.00-14.00 *Lunch, poster viewing*

## SESSION II: GASTRO-INTESTINAL CANCERS

Chairs: Annette Larsen, France and Alfredo Guglielmi, Italy

- 14.00-14.30 **Introductory remarks**  
Elizabeth Smyth, Cambridge University Hospital NHS Foundation Trust, UK
- 14.30-15.00 **TAK-ing aim at chemoresistance: the role of TGF beta pathway as therapeutic target in digestive tumors**  
Davide Melisi, University of Verona, Italy
- 15.00-15.30 **TGF- $\beta$  induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression**  
Adam Frampton, Imperial College of London, UK
- 15.30-16.00 **The new ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up of gastrointestinal stromal tumours**  
Iwona Lugowska, MSCMI, Warsaw, Poland
- 16.00-16.30 *Coffee break, poster viewing*
- 16.30-17.00 **New therapeutic opportunities from DNA damage repair to immunotherapy in pancreatic cancer**  
Giampaolo Tortora, Catholic University of Rome, Italy
- 17.00-17.30 **Surgery as adjuvant treatment in pancreatic cancer?**  
Claudio Bassi, University of Verona, Italy

## SATELLITE SYMPOSIUM SERVIER (NO ECM)

Chairs: Godefridus J. Peters, The Netherlands and Andrea Bonetti, Italy

- 17.30-18.15 **Present and future of trifluridine/tipiracil**  
Mario Scartozzi, University of Cagliari, Italy
- 18.15-18.45 **Presentation of three clinical cases**  
Alessandra Auriemma, Michele Pavarana, Jacopo Giuliani, Italy
- 18.45-19.00 **Discussion and closure**

## FRIDAY 8<sup>TH</sup> FEBRUARY

### SESSION III: NEW CHALLENGES IN DRUG RESISTANCE MECHANISMS

Chairs: Etienne Chatelut, France and Paola Perego, Italy

- 8.30-9.00      **Synthetic viability – mechanisms of drug resistance in BRCA1/2-deficient mouse mammary tumors**  
Sven Rottenberg, University of Bern, Switzerland
- 9.00-9.30      **Evolution and characterization of carboplatin resistance at single cell resolution**  
Oliver Harismendy– UCSD, La Jolla, CA, USA
- 9.30-10.00     **Oncogenic signaling pathways in the Cancer Genome Atlas**  
Giovanni Ciriello, University of Lausanne, Switzerland
- 10.00-10.30    *Coffee break, poster viewing*

### SESSION IV: ORAL COMMUNICATIONS 1

Chairs: Etienne Chatelut, France and Paola Perego, Italy

- 10.30-10.45    **The economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab**  
Jacopo Giuliani, Mater Salutis Hospital, Legnago, Italy
- 10.45-11.00    **New paradigms in the treatment of advanced renal cell carcinoma**  
Camillo Porta, Fondazione Maugeri, Pavia, Italy
- 11.00-11.15    **Analysis of predictive biomarkers in novel patient-derived xenograft (PDX) models of peritoneal metastasis from colorectal cancer (pmCRC)**  
Wolfgang Walther, University of Berlin, Germany
- 11.15-11.30    **Pharmacological and next-generation sequencing studies unravel multifactorial resistance to the novel antimetabolite RX-3117 in non-small cell lung cancer cells**  
Btissame El Hassouni, Amsterdam University Medical Center, VU University, The Netherlands
- 11.30-11.45    **Extracellular vesicles: subcellular organelles with the potential to spread cancer resistance**  
Fanny Ender, University of Luebeck, Germany
- 11.45-12.00    **Overcoming TRAIL resistance in cancer stem cells: computer-aided design of c-FLIP inhibitors**  
Kok Yung Lee, Cardiff University, UK
- 12.00-12.15    **Inhibition of stearyl-CoA desaturase 1 reverts BRAF and MEK inhibition induced selection of cancer stem cells in BRAF-mutated melanoma**  
Maria Elena Pisanu, Istituto Superiore di Sanità, Rome, Italy

### LECTURE **ECM**

- 12.15-13.00    **Mutational model in oncology: a new paradigm for the future?**  
Nello Martini, Presidente Fondazione Ricerca e Salute, Italy
- 13.00-14.00    *Lunch, poster viewing*

## FRIDAY 8<sup>TH</sup> FEBRUARY

### SESSION V: THORACIC CANCERS

Chairs: Alberto Amadori, Italy and Michele Milella, Italy

- 14.00-14.30 **Introductory remarks**  
Benjamin Besse, Gustave Roussy Cancer Campus, Paris, France
- 14.30-15.00 **Oncogene-addicted non-small-cell lung cancer: Treatment opportunities and future perspectives**  
Emilio Bria, Catholic University of Rome, Italy
- 15.00-15.30 **Splicing modulation as novel therapeutic strategy against diffuse malignant pleural and peritoneal mesothelioma**  
Elisa Giovannetti, Amsterdam University Medical Center, VU University, The Netherlands
- 15.30-16.00 *Coffee break, poster viewing*

### SESSION VI: ORAL COMMUNICATIONS 2

Chairs: Alberto Amadori, Italy and Michele Milella, Italy

- 16.00-16.15 **Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer, through reduced expression of SDHC**  
Gro Vatne Røslund, Haukeland University Hospital, Bergen, Norway
- 16.15-16.30 **Cytidine deaminase (CDA): a double-faced Janus in hematology oncology**  
Mélodie Donnette, Aix Marseille University, France
- 16.30-16.45 **Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line**  
Alessandro Leonetti, Amsterdam University Medical Center, VU University, The Netherlands
- 16.45-17.00 **Population pharmacokinetic modelling of etoposide in Ewing sarcoma patients**  
Farina Hellmann, University of Münster, Germany
- 17.00-17.15 **Pemetrexed treatment induces PD-L1 upregulation in NSCLC cell lines**  
Andrea Cavazzoni, University of Parma, Italy
- 17.15-17.30 **Development of ruthenium(II)-arene complexes as anticancer agents**  
Sandra Arandelović, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

### LECTURE **ECM**

- 17.30-18.00 **Cancer in movies and literature**  
Luciano Defiore, Sapienza University, Rome, Italy

18.00 **PAMM MEETING NO ECM**

20.30 **SOCIAL DINNER**

# SATURDAY 9<sup>TH</sup> FEBRUARY

## SESSION VII: BREAST CANCER

Chairs: Franco Muggia, USA and Stefania Gori, Italy

- |             |  |
|-------------|--|
| 8.30-9.00   | <b>Introductory remarks</b><br>Etienne Brain, Institut Curie, Hopital Rene Huguenin, Paris, France   |
| 9.00-9.30   | <b>Closing the gap between precision biology and personalized cancer medicine: the example of HER2 positive early breast cancer</b><br>Pierfranco Conte, Istituto Oncologico Veneto and University of Padua, Italy |
| 9.30-10.00  | <b>Multi-gene testing: from tissue to liquid biopsy in breast cancer</b><br>Gabriele Zoppoli, University of Genova, Italy  |
| 10.00-10.15 | <b>Optimizing CDK 4/6 inhibitors in breast cancer</b><br>Andrea Bonetti, Mater Salutis Hospital, Legnago, Italy  |
| 10.15-10.30 | <i>Coffee break, poster viewing</i>  |

## SESSION VIII: HAEMATOLOGICAL MALIGNANCIES

Chairs: Giovanni Martinelli and Fabio Benedetti, Italy

- |             |   |
|-------------|---|
| 10.30-11.00 | <b>Current advancements and future challenges in paediatric haematology oncology</b><br>Simone Cesaro, University Hospital of Verona, Italy |
| 11.00-11.30 | <b>Targeting bone marrow stromal support to haematological malignancies</b><br>Mauro Krampfer, University of Verona, Italy                  |
| 11.30-12.00 | <b>Pharmacometric considerations in the treatment of leukaemia in children</b><br>Georg Hempel, University of Münster, Germany              |

## THE BURGER-KELLAND LECTURE

- |             |   |
|-------------|---|
| 12.00-12.45 | <b>From targeted therapy to targeted therapy</b><br>Godefridus J. Peters, Laboratory Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands |
|-------------|---|

## 12.45 POSTER PRIZE AND CLOSURE

# THURSDAY 7<sup>TH</sup> - SATURDAY 9<sup>TH</sup> FEBRUARY

## POSTER PRESENTATIONS

Please note that the numbers listed correspond to the numbers of the poster boards

- P.01 **Interrogating the phosphoproteome for the selection of target candidates and (non-toxic) drug combinations in pancreatic ductal adenocarcinoma**  
Vallés MA, Amsterdam University Medical Center, VU University, The Netherlands
- P.02 **MicroRNAs as predictive biomarkers for response to systemic treatment in patients with pancreatic ductal adenocarcinoma**  
Boyd LNC, VUmc, Cancer Center Amsterdam, Department of Surgery, The Netherlands
- P.03 **MiR-21 as prognostic biomarker in radically resected cholangiocarcinomas**  
Garajová I, University Hospital of Parma, Italy
- P.04 **Attacking from all fronts: a comprehensive study of primary and secondary brain tumors focusing on the identification of therapeutic targets and the development of non-invasive diagnostic methods**  
Vieito Villar M, Vall d'Hebron Institute of Oncology, Spain
- P.05 **AXL downstream targeting unravels synergistic drug combinations in ovarian carcinoma cells**  
Corno C, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
- P.06 **Molecular mechanisms of AXL mediated drug resistance in NSCLC**  
Engelsen A, Dept. Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Norway
- P.07 **Biomechanical properties of PDAC affect key microRNAs expression and chemoresistance**  
Capula M, VUmc Cancer Center Amsterdam, Leiden University, The Netherlands
- P.08 **Consensus on doxorubicin dosing in infants and children: pharmacokinetic simulations and Delphi process**  
Siebel C, University Children's Hospital Muenster, Germany
- P.09 **Financial toxicity and non-small cell lung cancer treatment: the optimization in the choice of immune check point inhibitors**  
Giuliani J, Mater Salutis Hospital, Legnago, Italy
- P.10 **First-line therapy for metastatic non-small cell lung cancer: integrating clinical benefit with the cost of drugs**  
Giuliani J, Mater Salutis Hospital, Legnago, Italy
- P.11 **Grade  $\geq 3$  neutropenia and clinical outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil**  
Giuliani J, Mater Salutis Hospital, Legnago, Italy



- P.12 **Survival outcomes in metastatic colorectal cancer patients treated with panitumumab: the role of primary tumor side**  
Giuliani J, Mater Salutis Hospital, Legnago, Italy
- P.13 **Biological evaluation of new 1,2,4-oxadiazole topsentin analogs as anticancer agents**  
Parrino B, Dept. STEBICEF, University of Palermo, Italy
- P.14 **Preclinical activity of new imidazo [2,1-b][1,3,4] thiadiazoles derivatives on pancreatic cancer cells**  
Cascioferro S, Dept. STEBICEF, University of Palermo, Italy
- P.15 **Omics-based regulatory networks for the identification of disease driver pathways in platelets of patients with pancreatic cancer**  
Mantini G, Amsterdam University Medical Center, VU University, The Netherlands
- P.16 **Novel lactate dehydrogenase-A (LDH-A) inhibitors overcome chemoresistance of mesothelioma mediated by hypoxia**  
Li Petri G, Amsterdam University Medical Center, VU University, The Netherlands
- P.17 **Preclinical activity of the new nucleoside analogue RX-3117 against pancreatic cancer**  
Infante J, Amsterdam University Medical Center, VU University, The Netherlands
- P.18
- P.19 **Simultaneous quantification of asparaginases by capillary zone electrophoresis**  
Bauch T, Dept. Pharmaceutical and Medical Chemistry – Clinical Pharmacy, University of Muenster, Germany
- P.20 **microRNA signatures in liquid biopsies as biomarkers to predict resistance to targeted therapies in metastatic melanoma**  
Fattore L, Regina Elena National Cancer Institute, Rome, Italy
- P.21 **The anti-tumor efficacy of palbociclib, a CDK4/6 inhibitor, is enhanced by the combination with chemotherapy in triple negative breast cancer**  
Cretella D, Dept. of Medicine and Surgery, Lab. of Experimental Oncology, University of Parma, Italy
- P.22 **Why Immunoliposome and not ADC to extend trastuzumab to Her2 negative breast cancer models: a proof of concept study**  
Rodallec A, SMARTc Unit, Aix-Marseille University, France
- P.23 **Long-lasting (14 years) complete clinical response in an advanced BRCA2 mutation carrier pancreatic cancer patient treated with GEMOX as first line chemotherapy**  
Greco F, Mater Salutis Hospital, Legnago, Italy

## MEETING PLANNER

**RENBEL GROUP**  
*tailor-made professional services*



Renbel Travel Srl  
 Via Valpolicella, 1  
 37124 Verona | Italy  
 Tel. +39 045 7701150  
[events@renbelgroup.it](mailto:events@renbelgroup.it)

---

 Platinum Sponsorship
 

---




---

 Gold Sponsorship
 

---




---

 Silver Sponsorship
 

---

